<DOC>
	<DOCNO>NCT00044057</DOCNO>
	<brief_summary>The purpose study determine YM872 combination t-PA reduce disability brain damage stroke . YM872 placebo give continuous intravenous ( iv ) infusion 24 hour . It important study medication , YM872 placebo , administer prior completion t-PA administration . The clinical effect YM872 addition t-PA determine assess neurological function disability score follow visit Day 90 study .</brief_summary>
	<brief_title>A Study Evaluate Effects YM872 Brain Function Disability When Administered Combination With Alteplase ( Tissue Plasminogen Activator )</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Patients acute ischemic stroke treat alteplase within 3 hour stroke onset ( Onset define time patient last see normal state , bedtime unwitnessed stroke occur night ) . Patients able provide write informed consent consent provide legally authorize representative . Patients least 18 year age . Patients National Institutes Health Stroke Scale ( NIHSS ) score least 7 23 conscious . Other criterion specify study protocol Patients eligible receive treatment alteplase ( tPA ) due brain hemorrhage , risk hemorrhage , criterion . Patients stroke brainstem cerebellum . Patients renal ( kidney ) disease insufficiency . Patients active epilepsy convulsion current stroke episode . Patients IV drug user inebriate . Patients history drugrelated anaphylaxis . Patients take sedative , anticonvulsant , medication sedate effect 10 day prior study enrollment . Patients take 1.3 g aspirin per day 2 day prior enrollment . Patients know vitamin hypersensitivity . Other exclusion criterion specify study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>ARTIST</keyword>
</DOC>